↓ Skip to main content

The Alzheimer’s disease drug development landscape

Overview of attention for article published in Alzheimer's Research & Therapy, November 2021
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (93rd percentile)
  • High Attention Score compared to outputs of the same age and source (85th percentile)

Mentioned by

news
2 news outlets
twitter
33 X users

Citations

dimensions_citation
53 Dimensions

Readers on

mendeley
118 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
The Alzheimer’s disease drug development landscape
Published in
Alzheimer's Research & Therapy, November 2021
DOI 10.1186/s13195-021-00927-z
Pubmed ID
Authors

Pieter van Bokhoven, Arno de Wilde, Lisa Vermunt, Prisca S. Leferink, Sasja Heetveld, Jeffrey Cummings, Philip Scheltens, Everard G. B. Vijverberg

X Demographics

X Demographics

The data shown below were collected from the profiles of 33 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 118 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 118 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 17 14%
Student > Ph. D. Student 12 10%
Student > Master 9 8%
Student > Bachelor 9 8%
Other 8 7%
Other 15 13%
Unknown 48 41%
Readers by discipline Count As %
Neuroscience 19 16%
Pharmacology, Toxicology and Pharmaceutical Science 10 8%
Medicine and Dentistry 9 8%
Biochemistry, Genetics and Molecular Biology 7 6%
Agricultural and Biological Sciences 4 3%
Other 18 15%
Unknown 51 43%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 34. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 August 2023.
All research outputs
#1,172,010
of 25,383,344 outputs
Outputs from Alzheimer's Research & Therapy
#152
of 1,457 outputs
Outputs of similar age
#26,633
of 433,811 outputs
Outputs of similar age from Alzheimer's Research & Therapy
#7
of 42 outputs
Altmetric has tracked 25,383,344 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,457 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 26.6. This one has done well, scoring higher than 89% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 433,811 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 42 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 85% of its contemporaries.